santhera pharmaceuticals-reg
(SPHDF:OTC US)

Last --

Change Today 0.00 / 0.00%

Volume 0.0

SPHDF On Other Exchanges

Symbol

Exchange

SPHDF:US

OTC US

S3F:GR

Munich

SANN:SW

SIX Swiss Ex

All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (SPHDF) Snapshot

Open --		Previous Close --
Day High --		Day Low --
52 Week High 10/18/12 - $4.40		52 Week Low 12/6/12 - $4.10
Market Cap --		Average Volume 10 Days 0.0
EPS TTM --		Shares Outstanding 0.0
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for SANTHERA PHARMACEUTICALS-REG (SPHDF)

SPHDF:US Historical Stock Quote
SPHDF:US Advanced Stock Chart

Related News

No related news articles were found.

santhera pharmaceuticals-reg (SPHDF) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (SPHDF) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases in the areas of various orphan and niche indications. It offers Catena, a small molecule which is approved in Canada and available worldwide on special access programs for the treatment of Friedreich’s Ataxia. The compound is under regulatory review in Europe for treatment of Leber’s Hereditary Optic Neuropathy. The company’s products under development comprise Catena, which is also being developed for Duchenne Muscular Dystrophy (Phase III), MELAS syndrome (Phase IIa), and Primary Progressive Multiple Sclerosis (Phase I/II) indications; fipamezole for the treatment of Dyskinesia in Parkinson’s disease (Phase II/III); and omigapil, a molecule that is in preparation for a Phase I/II clinical development program in Congenital Muscular Dystrophies. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

Detailed SPHDF:US Company Description...

www.santhera.com

Founded in 2004

santhera pharmaceuticals-reg (SPHDF) Top Compensated Officers

Dr. Thomas Meier Ph.D.

Chief Executive Officer

Age: 50

Total Annual Compensation: SFr.389.0K

Executives, Board Directors

Compensation as of Fiscal Year 2012.

santhera pharmaceuticals-reg (SPHDF) Key Developments

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Apr 17 13

Santhera Pharmaceuticals Holding AG filed its Annual on Apr 17, 2013 for the period ending Dec 31, 2012. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Santhera Pharmaceuticals Holding AG Reports Consolidated Earnings Results for the Year 2012

Apr 16 13

Santhera Pharmaceuticals Holding AG reported consolidated earnings results for the year 2012. For the year, the company reported net sales of CHF 3,538,000 compared to CHF 3,265,000 a year ago. Operating loss was CHF 31,155,000 compared to CHF 27,213,000 a year ago. Net loss was CHF 31,448,000 compared to CHF 27,838,000 a year ago.

Santhera Pharmaceuticals Mulls Strategic Review

Feb 28 13

Santhera Pharmaceuticals Holding AG has appointed Piper Jaffray Ltd. to explore strategic options including product licensing for Raxone(®) in Leber's Hereditary Optic Neuropathy and the possibility of a merger or acquisition. The company has already received expressions of interest from third parties.